LIXTE BIOTECHNOLOGY HOLDINGS, INC. 8-K

What Happened
Lixte Biotechnology Holdings, Inc. (LIXT) announced a registered direct offering that closed on June 4, 2026, generating approximately $16.6 million in gross proceeds. The Company issued 2,366,503 shares of common stock and issued pre‑funded warrants to purchase an additional 258,859 shares. The securities were sold under the company’s existing Form S-3 shelf registration.

Key Details

• Offering closed: June 4, 2026.
• Securities sold: 2,366,503 common shares and pre‑funded warrants for 258,859 shares.
• Price: $6.31 per common share; $6.30 per pre‑funded warrant.
• Pre‑funded warrants: exercisable immediately at $0.0001 per share and exercisable until fully exercised.
• Gross proceeds: approximately $16.6 million (before offering expenses).
• Offering made pursuant to Form S-3 (File No. 333-278874), effectiveness date May 2, 2024.

Why It Matters
This transaction provides Lixte with fresh capital that increases its liquidity and financial resources to support ongoing operations and development programs. The issuance of shares and exercisable pre‑funded warrants will have dilutive effects when warrants are exercised. Investors should note the immediate exercisability and nominal exercise price of the pre‑funded warrants, the gross proceeds amount, and that the offering was completed under the company’s shelf registration.